ClinicalTrials.Veeva

Menu
E

Eye Research Foundation | Newport Beach, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Bimatoprost
Latanoprost
AR-15512
Timolol
AGN-151586
AMDX-2011P
RVL-1201
RGN-259
KPI-121
PF-04217329

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

22 of 111 total trials

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease (PREDICT-1)

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to ve...

Active, not recruiting
Dry Eye Disease (DED)
Other: Vehicle of licaminlimab
Other: Artificial Tear Run-in

The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle i...

Active, not recruiting
Pterygium
Drug: CBT-001
Drug: Vehicle

This study is evaluating a new eye drop containing pregabalin (TB0001) as a potential treatment for people with primary open-angle glaucoma or ocular...

Enrolling
Primary Open - Angle Glaucoma (POAG)
Ocular Hypertension (OHT)
Drug: Timolol 0.05% eye drops
Drug: Arm 2: TB0001 ophthalmic solution 1.2%

This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibo...

Active, not recruiting
Dry Eye Disease
Other: Vehicle
Drug: AZR-MD-001

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study

Enrolling
Open-angle Glaucoma
Ocular Hypertension
Drug: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Drug: Bimatoprost Ophthalmic Solution, 0.01%

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P...

Enrolling
Alzheimer Disease
Drug: AMDX-2011P

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P...

Enrolling
Cerebral Amyloid Angiopathy
Drug: AMDX-2011P

The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Op...

Enrolling
Primary Open Angle Glaucoma
Drug: AMDX-2011P

The purpose of this study is to assess the effectiveness and safety of a single dose of Corabotase (also known as IPN10200) compared to placebo (doub...

Active, not recruiting
Moderate to Severe Glabellar Lines
Biological: Corabotase
Biological: Placebo

The objective of this study is to evaluate the safety and efficacy of AGN-151586 for the treatment of moderate to severe forehead lines (FHL) in adul...

Active, not recruiting
Forehead Lines
Drug: AGN-151586

The objective of this Phase 2 study is to assess the safety and efficacy of single treatment of trenibotulinumtoxinE and onabotulibumtoxinA combinati...

Enrolling
Glabellar Lines
Upper Facial Lines
Drug: OnabotulinumtoxinA
Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA

This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co.,...

Enrolling
Ocular Hypertension (OH)
Primary Open Angle Glaucoma (POAG)
Drug: bimatoprost ophthalmic solution 0.01% (Lumigan®)
Drug: Bimatoprost ophthalmic solution 0.01% YSBP

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific musc...

Active, not recruiting
Glabellar Lines
Drug: BOTOX
Drug: AGN-151586

This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study i...

Active, not recruiting
Geographic Atrophy
Drug: BI 1584862
Drug: Placebo-matching BI 1584862

This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabeti...

Enrolling
Macular Edema
Drug: BI 1815368
Drug: Placebo

This is a Phase 2, randomized, multicenter, double masked, vehicle controlled, parallel group study to evaluate the efficacy and safety of DFL24498 t...

Enrolling
Dry Eye Disease (DED)
Other: Vehicle
Drug: DFL24498

This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonst...

Enrolling
Ocular Hypertension
Glaucoma, Open-Angle
Drug: Test - Bimatoprost 0.01% Ophthalmic Solution
Drug: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)

The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor...

Enrolling
Ocular Hyperemia
Drug: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free
Drug: Vehicle

The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressur...

Active, not recruiting
Ocular Hypertension
Glaucoma, Open-Angle
Combination Product: PA5108 Ocular Implant low dose
Drug: Latanoprost 0.005% Ophthalmic Solution

The goal of this clinical trial is to learn if Phentolamine Ophthalmic Solution works to treat adults that have had keratorefractive surgery and have...

Enrolling
Vision Loss Night
Vision Disorders
Drug: 0.75% Phentolamine Ophthalmic Solution
Drug: Placebo

Trial sponsors

Alcon logo
Allergan logo
AbbVie logo
Aerie Pharmaceuticals logo
A
F
S
Bausch + Lomb logo
Boehringer Ingelheim logo
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems